<DOC>
	<DOCNO>NCT02166827</DOCNO>
	<brief_summary>To evaluate long-term efficacy NeuroAD system</brief_summary>
	<brief_title>Effects NeuroAD System , Treatment Alzheimer Disease</brief_title>
	<detailed_description>To evaluate long-term efficacy NeuroAD system improvement mild- moderate Alzheimer patient ' cognitive function</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Main 1 . Male female age 6090 year 2 . Patients diagnose mild moderate stage Alzheimer 's Disease , accord DSMIV criterion 3 . MMSE score 18 26 4 . Physical clearance study participation evaluate clinician 5 . Spouse , family member professional caregiver agree capable take care participation patient study ( answer question regard patient 's condition assume responsibility medication ) 6 . Informed consent patient legally authorize person appoint Main 1 . CDR 0 , 0.5 3 2 . Severe agitation 3 . Mental retardation 4 . History Epileptic Seizures Epilepsy 5 . Contraindication perform MRI scan 6 . Contraindication receive TMS treatment accord TMS questionnaire 7 . Patients metal implant head , ( i.e . cochlear implant , implant brain stimulators neurostimulators , aneurysm clip ) exception metal implant mouth 8 . Cardiac pacemaker 9 . Implanted medication pump 10 . Intracardiac line 11 . Significant heart disease 12 . Currently take medication low seizure threshold</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TMS</keyword>
	<keyword>Cognitive Stimulation</keyword>
	<keyword>NeuroAD</keyword>
</DOC>